gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 31 Mar 2015.

Bruton agammaglobulinemia tyrosine kinase

Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, Syk, Tec, V1a
Papers using Btk antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
Supplier
von Lindern Marieke et al., In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Supplier
Nürnberg Bernd et al., In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
Supplier
El Khoury Joseph, In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Supplier
Nukiwa Toshihiro et al., In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on Btk
B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma.
Review
New
Staudt et al., Bethesda, United States. In Semin Hematol, 30 Apr 2015
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia.
New
Dhillon et al., Auckland, New Zealand. In Drugs, 24 Apr 2015
UNASSIGNED: Ibrutinib (Imbruvica(®)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.
Peroxiredoxin II is an antioxidant enzyme that negatively regulates collagen-stimulated platelet function.
New
Chang et al., South Korea. In J Biol Chem, 23 Apr 2015
PrxII-deficiency enhanced GPVI-mediated platelet activation through the defective elimination of H2O2 and the impaired protection of SH2 domain-containing tyrosine phosphatase-2 (SHP-2) against oxidative inactivation, which resulted in increased tyrosine phosphorylation of key components for GPVI signaling cascade, including Syk, Btk and phospholipase Cγ2.
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
New
Amiot et al., Nantes, France. In Oncotarget, 05 Apr 2015
Altogether, our data support the clinical application of ABT-199 therapy both as a single agent and in sequential combination with BTK inhibitors.
P8.07Novel mutational profiles in relapsed/refractory advanced cancer patients' pre- and post-targeted therapy.
New
Cooke et al., Memphis, United States. In Ann Oncol, 31 Mar 2015
Examples of acquired mutational profilies pre-/post- targeted therapy are highlighted including a patient with ALK translocated NSCLC treated with crizotinib plus AT13387 (HSP90 inhibitor) (Giri et al, NEJM 2014), rectal cancer (CDK4/6 inhibitor), uterine cancer (PI3K inhibitor), ovarian cancer (anti-PDL-1) and triple hit DLBCL (BTK inhibitor).
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Review
New
Redic et al., Ann Arbor, United States. In J Oncol Pharm Pract, 17 Mar 2015
New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, SAR650984), Bruton's tyrosine kinase inhibitors (ibrutinib), a selective inhibitor of nuclear export, and others.
MicroRNAs in B cell lymphomas: How a complex biology gets more complex.
Review
New
Mraz et al., Brno, Czech Republic. In Leukemia, Jan 2015
We focus on miR-contribution to the regulation of important signalling pathways (like NF-κB, PI3K/AKT, TGF-β), BCR signalling and its modulators (like PTEN, SHIP-1, ZAP-70, GAB1, BTK), anti- and pro-apoptotic proteins (like BCL2, MCL1, TCL1, BIM, p53, SIRT1), and transcription factors (like MYC, MYB, PU.1, FOXP1, BCL6).
Btk29A-Mediated Tyrosine Phosphorylation of Armadillo/β-Catenin Promotes Ring Canal Growth in Drosophila Oogenesis.
New
Yamamoto et al., Sendai, Japan. In Plos One, Dec 2014
Drosophila Btk29A is the ortholog of mammalian Btk, a Tec family nonreceptor tyrosine kinase whose deficit causes X-linked agammaglobulinemia in humans.
[State of the art treatment of progressive or refractory multiple myeloma].
Review
New
Engelhardt et al., Freiburg, Germany. In Dtsch Med Wochenschr, Oct 2014
Therefore, inclusion of patients in therapeutic trials and use of novel agent combinations is highly recommended, e.g. with 3(rd) generation-IMIDs (pomalidomide), new proteasome inhibitors, such as carfilzomib, ixazomib or oprozomib, antibodies, such as elotuzumab, daratumumab or SAR650984, siltuximab, tabalumab, denosumab, romosozumab, BTK-, HSP-inhibitors and other innovative phase I/II agents.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
New
Impact
O'Brien et al., Houston, United States. In Lancet Oncol, Sep 2014
BACKGROUND: Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL).
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
New
Impact
Oki et al., New York City, United States. In Lancet Oncol, Aug 2014
Pharmacodynamic data showed Bruton's tyrosine kinase was fully occupied (>90% occupancy) at the recommended phase 2 dose.
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
Review
New
Advani et al., Stanford, United States. In Ther Adv Hematol, Aug 2014
Bruton's tyrosine kinase (BTK), a protein early in this pathway, has emerged as a new therapeutic target in a variety of such malignancies.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
New
Impact
RESONATE Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Aug 2014
We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
Ibrutinib treatment of CLL: the cancer fights back.
New
Impact
Staudt et al., Bethesda, United States. In Cancer Cell, Aug 2014
Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
New
Impact
Byrd et al., Ulm, Germany. In N Engl J Med, Jul 2014
BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).
Tyrosine kinase Btk is required for NK cell activation.
GeneRIF
Cao et al., Shanghai, China. In J Biol Chem, 2012
Data suggest a role of tyrosine kinase Btk in the regulation of immune cell unctions and innate inflammatory response.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
GeneRIF
Nore et al., Huddinge, Sweden. In Mol Cell Biol, 2012
mapped the interaction site to the C terminus of the Btk SH3 domain
Single-chain variable fragment intrabody impairs LPS-induced inflammatory responses by interfering with the interaction between the WASP N-terminal domain and Btk in macrophages.
GeneRIF
Kitani et al., Tsukuba, Japan. In Biochem Biophys Res Commun, 2012
These observations strongly suggest that the phosphorylation of WASP by Btk plays a pivotal role in transducing the LPS signaling pathway in macrophages.
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
GeneRIF
Hendriks et al., Rotterdam, Netherlands. In Blood, 2012
Transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
GeneRIF
Lam et al., Singapore, Singapore. In Proc Natl Acad Sci U S A, 2012
BTK plays a critical role in initiating TLR3 signaling.
share on facebooktweetadd +1mail to friends